Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, DPX-Survivac, and Cyclophosphamide in Advanced Ovarian Cancer
NCT03029403Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Feb 2018
- Primary completion
- Dec 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of maveropepimut-S in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by University Health Network. Started Feb 2018; status: active, not recruiting.
02
Drugs
maveropepimut-S
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03029403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029403.